Business Context and Reporting Period
Arcutis Biotherapeutics, Inc. filed a Form 8-K dated June 8, 2021, reporting board changes and the results of its June 9, 2021 annual meeting of stockholders. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol ARQT.
Key Financial Metrics and Capitalization
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It states that 50,149,744 common shares were outstanding and entitled to vote as of the April 13, 2021 record date.
Material Changes
- Jonathan Silverstein informed the board of his resignation effective June 9, 2021. The filing states that the resignation was not related to any disagreement with the company or its operations, policies, or practices.
- Sue-Jean Lin was appointed as a Class II director, with a term expiring at the 2022 annual meeting, and joined the Nominating and Corporate Governance Committee.
- Ms. Lin received a stock option covering 25,723 shares, vesting in three equal annual installments subject to continued service. She is eligible for annual cash retainers of $40,000 for board service and $5,000 for committee service.
- The company will enter into its standard form of indemnification agreement with Ms. Lin. The filing reports no related-party transactions or family relationships requiring disclosure.
- Stockholders elected Terrie Curran, Halley Gilbert, and Ricky Sun, Ph.D. as Class I directors to serve until the 2024 annual meeting or until their successors are elected.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Annual Meeting Vote Results
| Proposal | For | Against or Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Terrie Curran election | 41,158,655 | 3,437,647 withheld | 6,872 | 2,118,077 |
| Halley Gilbert election | 44,544,519 | 51,785 withheld | 6,870 | 2,118,077 |
| Ricky Sun, Ph.D. election | 38,337,613 | 6,259,091 withheld | 6,470 | 2,118,077 |
| Ernst & Young LLP ratification | 46,684,509 | 30,633 | 6,109 | None |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The principal reported items are the director transition, the related equity and cash compensation arrangements, and the annual meeting results. The stock option and director retainers represent potential compensation expense, but the filing does not quantify the accounting impact.
Investor Verification Items
- Verify the effective date of Mr. Silverstein’s resignation and Ms. Lin’s appointment.
- Review the company’s director compensation program and the terms, exercise price, and accounting treatment of Ms. Lin’s 25,723-share option.
- Confirm the final board and committee composition following the annual meeting.
- Review subsequent filings for financial results, cash runway, financing activity, and any changes to the company’s operating outlook.